BURNABY, British Columbia, May 04, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 first quarter financial and operating results after the close of U.S. financial markets on Tuesday, May 9, 2017. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 19520816. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact: Jodi Regts Senior Director, Corporate Affairs Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]


Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 



